Member News
Covid-busting Nasal Spray Begins UK Trials January 11th
LONDON, UK — The first UK clinical trials of a nasal spray proven to kill 99.9% of the coronavirus that causes Covid-19 will begin on January 11th at Ashford and… Read More
Member News
AbCellera Biologics’s Billionaire Boss Planning Hiring Spree in Vancouver Hometown After Record-Setting IPO
After Carl Hansen co-founded AbCellera Biologics Ltd. in 2012, people constantly told him he was building a biotechnology company the wrong way. “The whole sector for years has been focused… Read More
Member News
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
VANCOUVER, BC – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in… Read More
Member News
Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
SEATTLE, WA – Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that on January 7, 2021, it received a clinical… Read More
Member News
Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences
VICTORIA, BC – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences and… Read More